UK Government adopts 44-point plan for flexible AI healthcare rules

flexible AI healthcare

Prime Highlights-

  • UK Government accepts all 44 National Commission recommendations to build a flexible AI healthcare regulatory system for evolving technology.
  • MHRA to monitor AI medical devices throughout their working life, replacing heavy reliance on one-off assessments with real-world performance checks.

Key Facts-

  • MHRA opens applications for third phase of AI Airlock sandbox, focused on post-market surveillance and lifecycle rules.
  • Staged authorization pathways could bring promising AI tools into the NHS sooner under close supervision.

Background-

The UK Government has backed every one of the 44 recommendations from the National Commission into the Regulation of AI in Healthcare, and the decision sets up a regulatory system that can adapt as AI technology develops.

A key change shifts oversight away from heavy reliance on one-off assessments of AI-enabled medical devices. Regulators will now track AI tools throughout their working life to check performance in real healthcare settings, which will help them spot safety issues as technologies evolve after launch.

The Medicines and Healthcare products Regulatory Agency (MHRA) will publish draft guidance on how to manage updates and improvements to AI-enabled medical devices. The agency also plans to consult on how to classify and qualify such devices.

The MHRA has opened applications for the third phase of its AI Airlock regulatory sandbox, where developers, regulators and healthcare organizations test how to introduce and monitor AI medical devices safely. This phase centers on post-market surveillance and lifecycle regulation, and it will gather evidence to shape future guidance.

The government also plans to explore staged authorization pathways that could bring promising AI tools into the NHS sooner under close supervision while real-world evidence builds. Patients will gain greater transparency about when AI is used in their care and clearer routes to seek redress.

A new Program Board will oversee delivery across government, the MHRA, NHS partners and the devolved administrations. Officials will release a complete plan soon that sets out the timeline and the owner for each of the 44 recommendations.

Read Also : GE HealthCare Builds Final Mile Footprint in U.S. PET Radiopharmaceutical Supply

Share:

Facebook
WhatsApp
Email
LinkedIn

Related Posts